Indian Immunologicals receives DCGI approval for measles-rubella vaccine

Indian Immunologicals Limited (IIL), a leading vaccine manufacturer has announced receipt of approval from Drugs Controller General of India and State Drug Control Administration for manufacturing of measles-rubella (MR) vaccine. This is the outcome of the Indo-Vietnam partnership, where IIL partnered with the Center for Research and Production of Vaccines and Biologicals, also called Polyvac, Vietnam. Measles causes severe, sometimes permanent, complications including pneumonia, seizures, brain damage, and even death. Measles is caused by a virus that lives in the nose and throat mucus of an infected person and spreads easily through breathing, coughing, and sneezing. There is no specific antiviral drug available to treat measles. The best way is to prevent measles through vaccination. The measles, mumps, rubella (MMR) vaccine is a safe and effective way to protect people from measles. Measles kills nearly 50,000 children every year in India. As there is not enough evidence to suggest that mumps is a disease of public health importance, MR vaccine is being used instead of MMR vaccine in India for routine immunization. India, along with other WHO Southeast Asia Region member countries, have resolved to eliminate measles and control rubella/congenital rubella syndrome (CRS). In this direction, the ministry of health & family welfare has been running MR vaccination campaigns in the age group of 9 months to less than 15 years in a phased manner across the nation. The measles-rubella campaign is a part of global efforts to reduce illness and deaths due to measles and rubella/CRS in the country. Measles immunization directly contributes to the reduction of under-five child mortality, and in combination with rubella vaccine, it will control rubella and prevent CRS. Under an exclusive agreement, Polyvac, Vietnam will supply the measles vaccine component to IIL. Rubella vaccine components will be produced by IIL to manufacture a combined MR vaccine. This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India. This vaccine has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years. Speaking on the occasion, Dr K Anand Kumar, managing director, Indian Immunologicals Limited said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!